[Featured Stock] Shinpoong Pharmaceutical Rises on Approval of Phase 3 Clinical Trial Plan for COVID-19 Treatment
[Asia Economy Reporter Park Soyeon] Shinpung Pharmaceutical is showing strong performance.
As of 10:02 AM on the 30th, Shinpung Pharmaceutical is trading at 72,600 KRW on the KOSPI market, up 6,200 KRW (9.34%) from the previous trading day.
On the 27th, Shinpung Pharmaceutical announced that it received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial plan of 'Piramex,' a malaria treatment drug being developed as a COVID-19 treatment.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Shinpung Pharmaceutical has a market capitalization of 3.8626 trillion KRW, ranking 88th on the KOSPI. The number of listed shares is 52,984,990.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
